Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783910 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia
A Phase 2 study, sponsored by Grünenthal.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT03783910 is a Phase 2 study that has completed, run by Grünenthal. The registered enrollment target is 90 participants.
The verdict
NCT03783910, a Phase 2 study, has completed, sponsored by Grünenthal.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo. Furthermore, it was to be found out if treatment with GRT9906 was safe and well-tolerated.
Interventions
- DRUG Placebo
- DRUG GRT9906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-09-19 |
| Est. Completion | 2006-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03783910
The ClinicalTrials.gov registry entry for NCT03783910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grünenthal, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03783910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03783910 about?
NCT03783910 is a clinical study titled "Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia". The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo. Furthermore, it was to be found out if treatment with GRT9906 was safe and well-tolerated.
What is the current status of trial NCT03783910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-09-19. Estimated completion is 2006-10-20.
What interventions are being tested in trial NCT03783910?
The interventions under investigation include: Placebo (DRUG), GRT9906 (DRUG).
Who is sponsoring clinical trial NCT03783910?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.